CDTX News and Press, Cidara Therapeutics Inc. From 11/29/22

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Institutional Shareholder Services (ISS) and...

Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily Rezafungin PDUFA target action date is scheduled for March 22, 2023 SAN DIEGO and PARSIPPANY, N.J., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, ...

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will p...

Summary Rezafungin has an FDA approval deadline of March 22, 2023. The stock has been neglected by investors. Even bigger success is possible in Cloudbreak co-development with Janssen. Cidara Therapeutics ( CDTX ) is a clinical stage biotechnology company with a mark...

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Ex...

Cidara Therapeutics press release ( NASDAQ: CDTX ): Q3 GAAP EPS of $0.17 beats by $0.10 . Revenue of $40.74M (+475.4% Y/Y) beats by $18.06M . For further details see: Cidara Therapeutics GAAP EPS of $0.17 beats by $0.10, revenue of $40.74M beats by $18.06...

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended...

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is presenting new clinical and preclinica...

Cidara Therapeutics ( NASDAQ: CDTX ) has announced receipt of an $11M milestone payment from Mundipharma under the licensing agreement established between the two companies in September 2019. The payment was made in association with the European Medicines Agency acceptance...

The shares of clinical-stage biotech Cidara Therapeutics ( NASDAQ: CDTX ) gained over 8% pre-market Tuesday after the company announced that British drugmaker Mundipharma paid $11.1M as a milestone payment under a 2019 licensing deal. The payment follows the acceptance...